Announcement on Voluntary Disclosure of Acceptance of New Drug Marketing Application for Treatment of Severe Alopecia Areata with Gecacitinib Hydrochloride Tablets

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Acceptance of New Drug Marketing Application for Treatment of Severe Alopecia Areata with Gecacitinib Hydrochloride TabletsThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A